Jan. 11 /PRNewswire/ -- Incyte Genomics, Inc. (Nasdaq: INCY - news), the leading genomic information company, announced today it has licensed its comprehensive microarray patent portfolio including U.S. Patent Numbers 5,716,785, 5,891,636, and 5,807,522, to Emeryville, CA-based biotechnology firm Chiron Corporation for internal use only. This technology complements Chiron's functional genomics program. Financial terms were not disclosed.
Incyte is the exclusive licensee to the '522 patent which was issued to Stanford University. The patent broadly covers methods for fabricating microarrays for applications such as gene expression analysis. The '522 patent describes proprietary technology used to print microarrays at densities greater than 100 polynucleotides per cm2. In its current format, this powerful technology allows for the fabrication of DNA arrays of at least 10,000 elements, each element representing a distinct gene. This key patent was based on pioneering work in the microarray field by Dari Shalon, Ph.D., of Incyte, and Patrick Brown, Ph.D., of Stanford University.
Incyte was granted an exclusive license under the '785 and '636 patents by Layton Bioscience, Inc. The technology was invented by James H. Eberwine, Russell N. Van Gelder, Mark E. Von Zastrow, and Jack D. Barchas. These patents cover a fundamental non-PCR based RNA amplification technology, which enables researchers to increase RNA sample size from cellular mRNA for use in microarray-based gene expression analysis.... |
